MARKET

VIVE

VIVE

Viveve Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.440
-0.070
-2.79%
After Hours: 2.420 -0.02 -0.82% 19:39 09/24 EDT
OPEN
2.480
PREV CLOSE
2.510
HIGH
2.510
LOW
2.320
VOLUME
269.62K
TURNOVER
--
52 WEEK HIGH
6.78
52 WEEK LOW
2.250
MARKET CAP
25.84M
P/E (TTM)
-0.3740
1D
5D
1M
3M
1Y
5Y
BRIEF-Viveve Medical Announces Issuance Of New Method Patent For Stress Urinary Incontinence In Australia
reuters.com · 1d ago
Viveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia
Patent strengthens and expands Viveve's intellectual property portfolio for the treatment of stress urinary incontinenceENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's in...
ACCESSWIRE · 1d ago
Viveve to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the H.
ACCESSWIRE · 09/07 12:28
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
BRIEF-Viveve Medical Q2 Revenue $1.7 Million
reuters.com · 08/12 22:14
Viveve Reports Second Quarter 2021 Financial Results and Provides Corporate Update
7M reported for Q2Reported sales of approximately 3,500 consumable treatment tips - a 42% unit increase quarter-over-quarterPivotal SUI PURSUIT trial enrollment on-track for completion in early Q4Potential long-term reimbursement pathway established with n...
ACCESSWIRE · 08/12 20:01
-- Earnings Flash (VIVE) VIVEVE MEDICAL Posts Q2 Revenue $1.65B
MT Newswires · 08/12 16:02
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VIVE. Analyze the recent business situations of Viveve Medical through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VIVE stock price target is 9.63 with a high estimate of 10.75 and a low estimate of 8.50.
EPS
Institutional Holdings
Institutions: 44
Institutional Holdings: 17.98M
% Owned: 169.76%
Shares Outstanding: 10.59M
TypeInstitutionsShares
Increased
5
101.30K
New
3
74.88K
Decreased
5
86.83K
Sold Out
5
73.59K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.19%
Healthcare Equipment & Supplies
-0.42%
Key Executives
Non-Executive Chairman/Independent Director
Steven Basta
Chief Executive Officer/Director
Scott Durbin
Senior Vice President
Jim Robbins
Director
Deborah Jorn
Independent Director
Arlene Morris
Independent Director
Sharon Presnell
No Data
About VIVE
Viveve Medical, Inc., incorporated on May 10, 2016, designs, develops, manufactures, and markets a platform medical technology, Cryogen-cooled Monopolar Radiofrequency (CMRF). The Company's CMRF technology is delivered through a radiofrequency (RF) generator, handpiece and treatment tip, that collectively, is referred to as the Viveve System. The Viveve System is marketed for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence (SUI), which is known as Viveve treatment. The Viveve System uses a method of delivering monopolar RF energy for treating tissue, such as Monopolar Radiofrequency Energy. Its Viveve System also uses a cryogen surface cooling that enables volumetric heating of vaginal tissue. Its treatment helps stabilize the underlying hypermobility of the urethra by regenerating collagen around the urethra's bladder neck. The Company's subsidiary includes Viveve, Inc. and Viveve BV.

Webull offers kinds of Viveve Medical Inc stock information, including NASDAQ:VIVE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIVE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIVE stock methods without spending real money on the virtual paper trading platform.